Immunovant, Inc. (IMVT) Stock

About Immunovant, Inc.

Immunovant, Inc. is led by CEO Eric Venker, employs 315 people, headquartered in Durham, US, publicly traded since 2019.

Immunovant, Inc. (IMVT) stock trades at $28.41 with a market capitalization of $5.87B. The stock is valued at a negative price-to-earnings (P/E) ratio of -11.98, reflecting a net loss over the last twelve months, price-to-book of 9.44, price-to-sales of 982.70. Over the past 52 weeks the stock has ranged between $15.95 and $45.42, and currently trades 37.5% below its 52-week high.

On profitability, Immunovant, Inc. generates a return on equity (ROE) of -69.59% (negative, reflecting a net loss), return on capital employed of -76.00%.

Immunovant, Inc. by the numbers, 2018–2026

Between 2018 and 2026 Immunovant, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-506.0M.

On a trailing twelve-month basis to Jun '26, revenue is $7.0M and net profit $-539.0M.

Borrowings stand at $0, cash from operations was $-407.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -50.3% over five years, and was -59.3% in the most recent year.

The share price itself has compounded at 14.4% a year over five years, 16.9% over three, 96.9% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Immunovant, Inc. (IMVT) — frequently asked questions